Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 924 Shares of Stock

Posted by Wayne Rhoads on Oct 24th, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 924 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $27,720.00. Following the completion of the transaction, the chief executive officer now directly owns 1,002,892 shares in the company, valued at approximately $30,086,760. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Samuel Kintz also recently made the following trade(s):

On Wednesday, October 9th, Samuel Kintz sold 16,710 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.15, for a total value of $470,386.50.
On Monday, October 7th, Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.50, for a total value of $75,075.00.
On Friday, October 4th, Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $335,787.06.
On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.54, for a total value of $14,486.04.
On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.89, for a total value of $274,680.00.
On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $62,561.20.
On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total value of $299,040.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $28.97 on Thursday. The stock’s 50-day simple moving average is $24.52 and its 200-day simple moving average is $22.88. The firm has a market capitalization of $1.36 billion, a PE ratio of -15.01 and a beta of 1.10. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. First Turn Management LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $9,657,000. Janus Henderson Group PLC grew its stake in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $4,489,000. Baker BROS. Advisors LP purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at approximately $2,020,000. Finally, Nicholas Investment Partners LP purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

View Our Latest Research Report on ELVN

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.